May 9th 2024
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Early Development of Regorafenib: Was the Correct Dose Selected?
February 11th 2016A first-in-human phase I dose-escalation study followed by a small expansion cohort, both of which were conducted solely in Germany, set the stage for what would soon become the FDA-approved dose for regorafenib (Stivarga) of 160 mg/day.
Read More
Clinical Review: Regorafenib in Refractory mCRC
February 11th 2016"While adverse events across both populations were broadly similar, some did occur more frequently in patients with longer exposure, an observation that is possibly related to the longer duration in this subgroup," said Axel Grothey, MD.
Read More
Optimizing Outcomes With Regorafenib in Metastatic CRC
February 11th 2016Regorafenib offers a unique challenge in terms of AE management. AEs with regorafenib have been reported across several clinical trials, and more recently, a clinical case study demonstrated the utility of regorafenib in a "real world" scenario, adding further insight.
Read More
Patient Populations Provide Sequencing Clues in Chemorefractory CRC
February 11th 2016To gain further insight into TAS-102 and regorafenib, Targeted Oncology spoke with Tanios Bekaii-Saab, MD, on how he utilizes currently available data to provide optimal care for patients with chemorefractory CRC.
Read More
Dr. Georgia L. Wiesner on the Importance of Genetic Testing for Colorectal Cancer
January 27th 2016Georgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, discusses the role genetic testing for colorectal cancer (CRC) plays in families.
Watch
First-in-Class Cancer Stemness Inhibitor Shows Promising Results in Advanced Colorectal Cancer
January 27th 2016The latest results from an open-label, phase Ib study of the STAT3 inhibitor BBI-608 (napabucasin) with a standard chemotherapy (FOLFIRI with or without bevacizumab) in the treatment of advanced colorectal cancer, have been presented at the ASCO 2016 Gastrointestinal Symposium. Evidence of antitumor activity and a favorable safety profile were seen in phase I studies.
Read More
Dr. Cathy Eng on Bevacizumab Plus FOLFOXIRI for Patients With mCRC.
January 22nd 2016Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC).
Watch
Dr. Cathy Eng on Bevacizumab Plus FOLFOXIRI for Patients With mCRC
January 22nd 2016Cathy Eng, MD, FACP, medical oncologist, The University of Texas MD Anderson Cancer Center, discusses the combination of bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as a treatment for patients with metastatic colorectal cancer (mCRC).
Watch
Neoadjuvant Radiation Regimen Efficacious, Less Toxic in Patients With Rectal Cancer
January 20th 2016Preoperative treatment with short-course radiation therapy plus 3 cycles of chemotherapy boosted overall survival (OS) and generated fewer adverse events (AEs) compared to standard chemoradiation for patients with locally advanced rectal cancer.
Read More
Gene Suppressing Some Cancer Types Could Be Lethal in Colorectal Cancer
January 5th 2016A gene associated with the suppression of tumor growth has been found to act in the opposite manner in some forms of colorectal cancer (CRC), according to researchers at the University of Missouri School of Medicine.
Read More
John L. Marshall, MD, Discusses the Growing Treatment Paradigm in CRC
January 4th 2016With an expanding treatment paradigm for patients with colorectal cancer (CRC) at their fingertips, oncologists are working out the best methods of use for their new armamentarium, says John L. Marshall, MD.
Read More
Metastatic Colorectal Cancer Target May Prove Promising for Subset of Patients
December 16th 2015Recent results from a survey of some 7000 patient specimens from the Cancer Genome Atlas concluded that gene fusion events, resulting in oncogenic activation, were commonly observed among members of the neurotrophic tyrosine receptor kinase family, with 23 gene fusions observed over a total of 9 different tumor types, including colorectal cancer.
Read More
Stakeholders Urge Congress to Pass Screening Act for Colorectal Cancer
November 13th 2015A number of colorectal cancer care advocacy groups and the American Cancer of Radiology are lobbying Congress to pass the CT Colonography Screening for Colorectal Cancer Act, an initiative that could lower costs and increase screening rates.
Read More
Dr. S Yousuf Zafar Talks About BMI and Survival Rates in Colorectal Cancer Patients
October 16th 2015Dr. S. Yousuf Zafar talks about the association between the body mass index of patients who are starting treatment for colorectal cancer and both the progression free survival and overall survival.
Watch
New Genome Characterization Center to Focus on Proteomics Across Tumor Types
July 27th 2015The University of Texas MD Anderson Cancer Center in Houston has been selected as the site for one of two new Genome Characterization Centers (GCCs) funded by the National Cancer Institute (NCI) and National Institute of Health (HHSN261200800001E).
Read More
Advantages of Using Y-90 for the First-Line Treatment of Patients With Liver Metastases from mCRC
July 24th 2015Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, discusses the advantages of using yttrium-90 (Y-90) as the first line treatment for patients with liver metastases from metastatic colorectal cancer (mCRC).
Watch
Efficacy of Blinatumomab Presented in Phase II Ph+ ALL Study
July 20th 2015According to findings from a phase II study released by Amgen, monotherapy with blinatumomab (Blincyto) showed promising complete remission (CR) or CR with partial hematological recovery (CRh) rates in adult patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) B cell precursor acute lymphoblastic leukemia (ALL).
Read More
Proteomic Study in CRC of Paired Tumor Versus Nontumor Tissue May Identify New Biomarkers
July 16th 2015One gene can encode more than one protein; however, proteins are dynamic (binding to membranes, other proteins, synthesis, degradation), undergo co- and post-translational modification, and exist in a wide range of concentrations in the body.
Read More